Taken together, these findings suggest that C1QC+ RTMs may promote antitumor immunity in CRC patients receiving ICI treatment by enhancing their interaction with CD4+ T cells through upregulation of MHC-II molecule expression. Here, CD4 is linked to colorectal carcinoma.